Characterization of reactive intermediates formation in dacomitinib metabolism and bioactivation pathways elucidation by LC-MS/MS: in vitro phase I metabolic investigation

Dacomitinib (DCB) is a second generation irreversible tyrosine kinase inhibitor (TKI) that is claimed to overcome the disadvantages of the resistance developed by the first line epidermal growth factor receptor (EGFR) TKIs. In the current study, metabolites of phase I for DCB were systematically exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Attwa, Mohamed W., Kadi, Adnan A., Abdelhameed, Ali S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2018
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090608/
https://www.ncbi.nlm.nih.gov/pubmed/35558335
http://dx.doi.org/10.1039/c8ra06709k

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090608/
https://www.ncbi.nlm.nih.gov/pubmed/35558335
http://dx.doi.org/10.1039/c8ra06709k

Ejemplares similares